Loading...
XNAS
BMRA
Market cap9mUSD
Jul 25, Last price  
3.91USD
1D
-5.56%
1Q
0.77%
Jan 2017
70.00%
Name

Biomerica Inc

Chart & Performance

D1W1MN
P/E
—
P/S
1.84
EPS
—
Div Yield, %
—
Shrs. gr., 5y
12.80%
Rev. gr., 5y
0.81%
Revenues
5m
+1.42%
9,273,9807,184,9925,748,3194,926,5054,934,7715,075,2224,899,3756,081,1316,472,9605,120,4514,962,3735,139,8165,791,6705,564,1855,200,6826,692,7117,199,02718,871,4095,339,0005,415,000
Net income
-6m
L-16.27%
162,259230,273536,8791,710,044354,180-331,455157,447548,435536,957-215,660-331,410-1,499,787-908,561-1,465,828-2,393,060-2,339,054-6,469,036-4,531,044-7,140,000-5,978,000
CFO
-5m
L-2.06%
72,920-385,169463,708-194,595-101,999-236,980328,803147,4121,394,037-862,273-405,481-208,782-722,858-1,174,217-2,244,039-4,297,498-5,251,748-480,532-5,474,000-5,361,000
Earnings
Aug 26, 2025

Profile

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
URL
https://biomerica.com/
IPO date
Mar 17, 1980
Employees
62
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑052023‑052022‑052021‑052020‑052019‑052018‑052017‑052016‑05
Income
Revenues
5,415
1.42%
5,339
-71.71%
Cost of revenue
6,295
6,477
Unusual Expense (Income)
NOPBT
(880)
(1,138)
NOPBT Margin
Operating Taxes
42
51
Tax Rate
NOPAT
(922)
(1,189)
Net income
(5,978)
-16.27%
(7,140)
57.58%
Dividends
Dividend yield
Proceeds from repurchase of equity
(81)
9,309
BB yield
0.83%
-48.01%
Debt
Debt current
326
297
Long-term debt
1,244
1,867
Deferred revenue
Other long-term liabilities
Net debt
(2,765)
(7,720)
Cash flow
Cash from operating activities
(5,361)
(5,474)
CAPEX
(51)
(78)
Cash from investing activities
(115)
(78)
Cash from financing activities
(81)
9,390
FCF
(870)
(831)
Balance
Cash
4,170
9,719
Long term investments
165
165
Excess cash
4,064
9,617
Stockholders' equity
(46,951)
(40,981)
Invested Capital
54,327
53,787
ROIC
ROCE
EV
Common stock shares outstanding
16,822
14,154
Price
0.58
-57.62%
1.37
-60.86%
Market cap
9,767
-49.63%
19,391
-56.28%
EV
7,002
11,671
EBITDA
(506)
(787)
EV/EBITDA
Interest
Interest/NOPBT